Biomarkers for Diagnosis, Complications and Therapy Effects in Civilization Diseases Management

doi:10.3390/books978-3-0365-3745-0

Download Url(s)

https://mdpi.com/books/pdfview/book/5293

Contributor(s)

Komosinska-Vassev, Katarzyna (editor)

Olczyk, Pawel (editor)

Language

English

Show full item record

Abstract

This Special Issue contributes original research and review articles on the role of new protein, molecular, and genetic markers used for the diagnosis and progression of civilization diseases, as well as biomarkers useful in the monitoring the effects of the implemented treatment.

URI

https://directory.doabooks.org/handle/20.500.12854/80955

Keywords

pharmacogenomics; NGS variants; personalized medicine; FSHR; personalized drug therapy; hedgehog-interacting protein; impaired fasting glucose; impaired glucose tolerance; newly diagnosed diabetes; normal glucose tolerance; inflammatory bowel disease; ulcerative colitis; Crohn’s disease; extracellular matrix components; hyaluronan; inflammatory bowel diseases (IBD); Crohn’s disease (CD); ulcerative colitis (UC); sulfated glycosaminoglycans (sGAG); hyaluronan (HA); soluble part of syndecan-1 (sCD138); microRNA; cardiovascular disease; diabetes; mortality; antiplatelet therapy; platelet reactivity; Let-7e; miR-126; miR-223; miR-125a-3p; CCL11; CCL24; CCL26; CCR3; CRC; adiponectin; adipokines; rheumatology; obesity; overweight; case control study; rheumatoid arthritis; TNF-α inhibitors; bone turnover markers; PINP; PICP; NTX-I; CTX-I; RANKL/OPG; ovarian cancer; interleukin 21; interleukin 22; lymphocytes; macrophages; dendritic cells; innate lymphoid cells; breast cancer; extracellular matrix; proteins; tumorigenesis; tumor microenvironment